<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000767620"><TermName>recombinant human papillomavirus nonavalent vaccine</TermName><TermPronunciation>(ree-KOM-bih-nunt HYOO-mun PA-pih-LOH-muh-VY-rus NOH-nuh-VAY-lent vak-SEEN)</TermPronunciation><TermDefinition><DefinitionText>A vaccine used to prevent anal, cervical, vulvar, and vaginal cancer caused by human papillomavirus (HPV) types 16, 18, 31, 33, 45, 52 and 58 and genital warts caused by HPV types 6 and 11. Recombinant human papillomavirus nonavalent vaccine is approved for use in males aged 9 to 15 years and females aged 9 to 26 years. It is a type of nonavalent vaccine (a vaccine that works against nine different viruses or other microorganisms). Also called Gardasil 9.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000769331" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;recombinant human papillomavirus nonavalent vaccine&quot;" language="en" id="_4"/><MediaLink ref="CDR0000769330" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;vacuna nonavalente recombinante contra el virus del papiloma humano&quot;" language="es" id="_3"/><SpanishTermName>vacuna nonavalente recombinante contra el virus del papiloma humano</SpanishTermName><SpanishTermDefinition><DefinitionText>Vacuna que se usa para prevenir los cánceres anales, de cuello uterino, de vulva y de vagina causados por los tipos 16, 18, 31, 33, 45, 52 y 58 del virus del papiloma humano (VPH), así como las verrugas genitales causadas por los tipos 6 y 11 del VPH. El uso de la vacuna genotecnológica nanovalente contra el virus del papiloma humano está aprobado para varones de 9 a 15 años  y mujeres de 9 a 26 años. Es un tipo de vacuna nonavalente (una vacuna que es eficaz contra nueve virus diferentes u otros microorganismos). También se llama Gardasil 9.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2014-12-29</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000767283">Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
